Antisense Oligonucleotides for Exon 80 Skipping in COL7A1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dystrophic epidermolysis bullosa (DEB) are limited, with no effective therapies available, and existing antisense oligonucleotides (AONs) for exon 80 skipping in the COL7A1 gene have low efficiency, necessitating the development of more effective AONs to improve exon skipping and collagen VII production.
Innovation Solution
Design and use of shorter antisense oligonucleotides (AONs) that are complementary to exon 80 and its downstream intron, specifically targeting the boundary between exon 80 and the downstream intron, with sequences such as 5'-UCACCACU-3', 5'-ACCACUGG-3', and 5'-ACUCACCA-3', to enhance exon skipping efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing antisense oligonucleotides (AONs) are used to target exon 80, then exon skipping is achieved, but the efficiency is low
Solution Approach 1:
The patent changes the parameters of the AONs by reducing their length from the conventional 24 nucleotides to 20-23 nucleotides, and by optimizing the sequence composition and binding location. This parameter optimization results in improved exon skipping efficiency while maintaining treatment effectiveness for DEB
Solution Approach 2:
The patent applies local quality by precisely positioning the AON binding site at the boundary between exon 80 and the downstream intron, rather than using conventional binding sites. This localized targeting approach enhances the specificity and efficiency of exon skipping at the critical splice site region
2Stability of the object's composition
If longer antisense oligonucleotides are used, then binding stability is improved, but the complexity of synthesis and purification increases
Solution Approach 1:
The patent optimizes the parameter of oligonucleotide length by reducing it from 24 to 20-23 nucleotides. This change maintains sufficient binding stability through optimized sequence composition while significantly reducing the complexity of synthesis and purification processes
3Ease of manufacture
If conventional AON sequences are used, then manufacturing is straightforward, but exon skipping efficiency is insufficient
Solution Approach 1:
The patent optimizes the sequence parameters of the AONs by selecting specific 20-23 nucleotide sequences with optimized GC content and binding characteristics. These parameter changes enhance exon skipping efficiency while maintaining manufacturing feasibility through standard synthesis protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new AONs demonstrate improved exon skipping efficiency, leading to the production of a functional, shorter collagen VII protein, potentially offering a more effective treatment for DEB by reducing exon 80 inclusion in human COL7A1 mRNA.
Implementation Method 1
the oligonucleotide (a) comprises a nucleotide sequence which is complementary to part of exon 80
Data Source
AI summary
An antisense oligonucleotide capable of preventing or reducing exon 80 inclusion into a human COL7A1 mRNA, and methods for preventing or reducing exon 80 inclusion into a human COL7A1 mRNA.